Valsartan-d8

• Description :

  Valsartan-d8 is the deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research[1].

• CAS Number :

  [1089736-72-0]

• Product Name Alternative :

  CGP 48933-d8

• UNSPSC :

  12352005

• Target :

  Angiotensin Receptor

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  GPCR/G Protein

• Field of Research :

  Cardiovascular Disease; Endocrinology

• Purity :

  99.90

• Solubility :

  10 mM in DMSO|DMSO : 50mg/mL (ultrasonic) |H2O : 1mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  [2H]C([2H])([2H])C(C([2H])([2H])[2H])([2H])[C@](C(O)=O)([2H])N(C(CCCC)=O)CC1=CC=C(C=C1)C2=C(C3=NN=NN3)C=CC=C2

• Molecular Formula :

  C24H21D8N5O3

• Molecular Weight :

  443.57

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Shan H, et al. Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity. J Cell Mol Med. 2014 Jun;18 (6) :1071-80.|[3]Wang Y, et al. Valsartan blocked alcohol-induced, Toll-like receptor 2 signaling-mediated inflammation in human vascular endothelial cells. Alcohol Clin Exp Res. 2014 Oct;38 (10) :2529-40.|[4]Sui X, et al. Novel mechanism of cardiac protection by valsartan: synergetic roles of TGF-β1 and HIF-1α in Ang II-mediated fibrosis after myocardial infarction. J Cell Mol Med. 2015 Aug;19 (8) :1773-82.|[5]Jiang Y, et al. Cardioprotective effect of valsartan in mice with short-term high-salt diet by regulating cardiac aquaporin 1 and angiogenic factor expression. Cardiovasc Pathol. 2015 Jul-Aug;24 (4) :224-9.|[6]Ping G, et al. Valsartan reverses depressive/anxiety-like behavior and induces hippocampal neurogenesis and expression of BDNF protein in unpredictable chronic mild stress mice. Pharmacol Biochem Behav. 2014 Sep;124:5-12.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported